Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib
BRAF inhibitors are broadly used for metastatic melanoma with BRAF mutations. Their use results in various cutaneous side effects, such as the development of keratoacanthomas and squamous cell carcinomas. We report a patient with metastatic melanoma treated with vemurafenib who developed dozens of h...
Saved in:
Main Authors: | Carine Houriet (Author), Natalie D. Klass (Author), Helmut Beltraminelli (Author), Luca Borradori (Author), Patrick A. Oberholzer (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2014-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of BRAF inhibitor (Vemurafenib) in a child with Refractory Langerhans cell histiocytosis
by: Anil Sharma, et al.
Published: (2017) -
Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
by: A. S. Kolbin, et al.
Published: (2018) -
Vemurafenib-Induced Toxic Epidermal Necrolysis: An Emerging Adverse Event
by: Ana Filipe Monteiro, et al.
Published: (2018) -
A diagnostic dilemma: Atypical melanocytic lesions arising in the setting of treatment with the BRAF inhibitor, vemurafenib
by: Mary Clark, MD, et al.
Published: (2022) -
Adult‐onset BRAF V600E‐related multisystem Langerhans cell histiocytosis treated with vemurafenib
by: Lisa Denise A. Encarnacion‐Mangubat, et al.
Published: (2024)